NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for cardiovascular disease patients with elevated LDL-C, has announced its participation in the Guggenheim SMID Cap Biotech Conference.
The company's Chief Financial Officer, Ian Somaiya, will engage in a fireside chat on Wednesday, February 5, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast through NewAmsterdam Pharma's investor relations website at ir.newamsterdampharma.com. An archived replay will be available on the company's website following the live presentation.
NewAmsterdam Pharma (Nasdaq: NAMS), una società biofarmaceutica clinica in fase avanzata focalizzata sullo sviluppo di farmaci orali non statinici per pazienti con malattie cardiovascolari e elevati livelli di LDL-C, ha annunciato la sua partecipazione alla Guggenheim SMID Cap Biotech Conference.
Il Chief Financial Officer dell'azienda, Ian Somaiya, parteciperà a una chiacchierata informale mercoledì 5 febbraio 2025, alle 10:00 ET. Gli investitori e le parti interessate possono accedere alla trasmissione in diretta tramite il sito web delle relazioni con gli investitori di NewAmsterdam Pharma all'indirizzo ir.newamsterdampharma.com. Una registrazione dell'evento sarà disponibile sul sito dell'azienda dopo la presentazione dal vivo.
NewAmsterdam Pharma (Nasdaq: NAMS), una compañía biofarmacéutica en etapa avanzada enfocada en desarrollar medicamentos orales no estatinicos para pacientes con enfermedades cardiovasculares y niveles elevados de LDL-C, ha anunciado su participación en la Guggenheim SMID Cap Biotech Conference.
El Director Financiero de la compañía, Ian Somaiya, participará en una charla informal el miércoles 5 de febrero de 2025, a las 10:00 a.m. ET. Los inversores y partes interesadas pueden acceder a la webcast en vivo a través del sitio web de relaciones con inversores de NewAmsterdam Pharma en ir.newamsterdampharma.com. Una grabación estará disponible en el sitio web de la compañía después de la presentación en vivo.
NewAmsterdam Pharma (Nasdaq: NAMS)는 높은 LDL-C 수치를 가진 심혈관 질환 환자를 위한 비스타틴 경구 약물 개발에 중점을 둔 후기 단계의 임상 생물제약 회사로, 구겐하임 SMID 캡 바이오테크 컨퍼런스에 참여한다고 발표했습니다.
회사의 최고재무책임자(CFO)인 Ian Somaiya는 2025년 2월 5일 수요일 오전 10:00 ET에 화상 대화에 참여할 예정입니다. 투자자와 관련된 이해관계자는 NewAmsterdam Pharma의 투자자 관계 웹사이트인 ir.newamsterdampharma.com을 통해 생중계를 시청할 수 있습니다. 생중계 후 회사 웹사이트에 아카이브된 다시 보기 버전이 제공될 것입니다.
NewAmsterdam Pharma (Nasdaq: NAMS), une entreprise biopharmaceutique en phase avancée axée sur le développement de médicaments oraux non-statiniques pour les patients atteints de maladies cardiovasculaires avec des niveaux élevés de LDL-C, a annoncé sa participation à la Guggenheim SMID Cap Biotech Conference.
Le directeur financier de la société, Ian Somaiya, participera à une discussion informelle le mercredi 5 février 2025, à 10h00 ET. Les investisseurs et les parties intéressées peuvent accéder à la diffusion en direct via le site web des relations avec les investisseurs de NewAmsterdam Pharma à l'adresse ir.newamsterdampharma.com. Un enregistrement sera disponible sur le site de l'entreprise après la présentation en direct.
NewAmsterdam Pharma (Nasdaq: NAMS), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung oraler, nicht-statinischer Medikamente für Patienten mit Herz-Kreislauf-Erkrankungen und erhöhtem LDL-C konzentriert, hat seine Teilnahme an der Guggenheim SMID Cap Biotech Conference bekannt gegeben.
Der Chief Financial Officer des Unternehmens, Ian Somaiya, wird am Mittwoch, den 5. Februar 2025, um 10:00 Uhr ET an einem Fireside-Chat teilnehmen. Investoren und interessierte Parteien können die Live-Webcast über die Investor-Relations-Website von NewAmsterdam Pharma unter ir.newamsterdampharma.com abrufen. Eine archivierte Wiederholung wird nach der Live-Präsentation auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
NAARDEN, The Netherlands and MIAMI, Jan. 29, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that Ian Somaiya, Chief Financial Officer of NewAmsterdam Pharma, will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 10:00 a.m. ET.
A live webcast of the fireside chat will be available through the investor relations section of the NewAmsterdam Pharma website at ir.newamsterdampharma.com. Following the live webcast, an archived replay will be available on the Company’s website.
About NewAmsterdam
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. We seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated.
Company Contact
Matthew Philippe
P: 1-917-882-7512
matthew.philippe@newamsterdampharma.com
Media Contact
Spectrum Science on behalf of NewAmsterdam
Jaryd Leady
P: 1-856-803-7855
jleady@spectrumscience.com
Investor Contact
Precision AQ on behalf of NewAmsterdam
Austin Murtagh
P: 1-212-698-8696
austin.murtagh@precisionaq.com
FAQ
When is NewAmsterdam Pharma (NAMS) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch NewAmsterdam Pharma's (NAMS) Guggenheim Conference presentation?
What type of medicines is NewAmsterdam Pharma (NAMS) developing?
Who will represent NewAmsterdam Pharma (NAMS) at the Guggenheim SMID Cap Biotech Conference?
